Skip to main content

brinsupri

Generic: BRENSOCATIB

brinsupri: developed by 1 company · 1 FDA decision.

brinsupri evidence translation

What we can confirm

1 FDA record

What it means

Source-backed records connect brinsupri to INSM; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could brinsupri → INSM affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
INSMED Inc (INSM)
Non-cystic fibrosis bronchiectasis (NCFB) in patients 12 yea…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. ( 1 )(INSM)FDA ↗
NDA217673Type 1 - New Molecular EntityPriorityOralTablet

Frequently asked questions

Who is developing brinsupri?

brinsupri is being developed by INSMED Inc.

What is brinsupri's latest FDA decision?

The most recent tracked FDA decision for brinsupri is Approval for 1 INDICATIONS AND USAGE BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. ( 1 ), dated August 12, 2025.